Connect with Us

Covington Advises OVP Venture Partners on Fate Therapeutics Financing

November 16, 2009

SAN FRANCISCO, CA, November 16, 2009 — Fate Therapeutics, Inc. announced today that it has completed a $30 million series B financing led by OVP Venture Partners. Covington & Burling LLP advised OVP on the transaction. Also participating in the financing were ARCH Venture Partners, Polaris Venture Partners and Venrock, which collectively led the company’s series A financing, and a syndicate of corporate investors including Astellas Venture Management, Genzyme Corporation and a third undisclosed corporate investor.

Connect with Us

Covington & Burling LLP operates as a limited liability partnership worldwide, with the practice in England and Wales conducted by an affiliated
limited liability multinational partnership, Covington & Burling LLP, which is formed under the laws of the State of Delaware in the United States
and authorized and regulated by the Solicitors Regulation Authority with registration number 77071.